137 related articles for article (PubMed ID: 26165320)
21. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
22. DNA polymerase ζ limits chromosomal damage and promotes cell survival following aflatoxin exposure.
Lin YC; Owen N; Minko IG; Lange SS; Tomida J; Li L; Stone MP; Wood RD; McCullough AK; Lloyd RS
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13774-13779. PubMed ID: 27849610
[TBL] [Abstract][Full Text] [Related]
23. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir.
Jamwal RS; Mahajan N; Bhat GR; Bhat A; Shah R; Verma S; Sharma M; Sharma B; Qadri RA; Kumar R; Bhat A
Cancer Epidemiol; 2021 Dec; 75():102047. PubMed ID: 34655923
[TBL] [Abstract][Full Text] [Related]
24. SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways.
Tang F; Hu P; Yang Z; Xue C; Gong J; Sun S; Shi L; Zhang S; Li Z; Yang C; Zhang J; Xie C
Oncol Rep; 2017 Jun; 37(6):3449-3458. PubMed ID: 28498429
[TBL] [Abstract][Full Text] [Related]
25. Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells.
Wittschieben JP; Reshmi SC; Gollin SM; Wood RD
Cancer Res; 2006 Jan; 66(1):134-42. PubMed ID: 16397225
[TBL] [Abstract][Full Text] [Related]
26. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
27. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
28. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
Vassel FM; Bian K; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28922-28924. PubMed ID: 33144509
[TBL] [Abstract][Full Text] [Related]
29. The role of DNA polymerase ζ in benzo[a]pyrene-induced mutagenesis in the mouse lung.
Ishii Y; Takasu S; Grúz P; Masumura K; Ogawa K; Nohmi T; Umemura T
Mutagenesis; 2021 May; 36(2):155-164. PubMed ID: 33544859
[TBL] [Abstract][Full Text] [Related]
30. Impaired DNA double-strand breaks repair by kinesin family member 4A inhibition renders human H1299 non-small-cell lung cancer cells sensitive to cisplatin.
Wan Q; Shen Y; Zhao H; Wang B; Zhao L; Zhang Y; Bu X; Wan M; Shen C
J Cell Physiol; 2019 Jul; 234(7):10360-10371. PubMed ID: 30417376
[TBL] [Abstract][Full Text] [Related]
31. REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase ζ.
Tomida J; Takata K; Lange SS; Schibler AC; Yousefzadeh MJ; Bhetawal S; Dent SY; Wood RD
Nucleic Acids Res; 2015 Jan; 43(2):1000-11. PubMed ID: 25567983
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2.
Wang Y; Li F; Ma D; Gao Y; Li R; Gao Y
Mol Med Rep; 2019 Oct; 20(4):3519-3526. PubMed ID: 31485614
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
34. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).
Wang Q; Zhong M; Liu W; Li J; Huang J; Zheng L
Exp Lung Res; 2011 Sep; 37(7):427-34. PubMed ID: 21787234
[TBL] [Abstract][Full Text] [Related]
35. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.
Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H
Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752
[TBL] [Abstract][Full Text] [Related]
36. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
Srivastava AK; Han C; Zhao R; Cui T; Dai Y; Mao C; Zhao W; Zhang X; Yu J; Wang QE
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4411-6. PubMed ID: 25831546
[TBL] [Abstract][Full Text] [Related]
37. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
38. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
Li N; Li X; Li S; Zhou S; Zhou Q
Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
[TBL] [Abstract][Full Text] [Related]
40. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
